SGM
RETA

Skye Global Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Skye Global Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,500
Closed -$920K – 81
2021
Q2 		$920K Buy
+6,500
New +$734K 0.02% 51

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Skye Global Management's RETA Position: Q3 2021 in Review

Skye Global Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 6,500 shares — an estimated $920K sold.

Skye Global Management first reported a position in RETA in Q2 2021 and held it in 1 quarter. The position peaked at $920K in Q2 2021. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

  • Skye Global Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
  • Skye Global Management sold 6,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $920K.
  • Skye Global Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2021 and held it in 1 quarter.
  • Skye Global Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $920K in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on Skye Global Management's 13F filing for Q3 2021, filed 15 Nov 2021.